Th17 Cells and autoimmune encephalomyelitis (EAE/MS).

Area of Science:

• Immunology
• Neuroscience
• Autoimmunity

Background:

• Multiple sclerosis (MS) is a CD4+ T cell-mediated autoimmune central nervous system disorder.
• Historically, Th1 cells (IL-12 driven) were considered pathogenic in MS and EAE.
• Emerging evidence highlights the critical role of Th17 cells (IL-23 driven) in EAE pathogenesis.

Purpose of the Study:

• To investigate the role of IL-23/Th17 axis in the pathogenesis of multiple sclerosis.
• To identify specific markers for human Th17 cells involved in MS.
• To explore potential therapeutic targets within the Th17 cell pathway for MS treatment.

Main Methods:

• Analysis of T cell differentiation pathways involving cytokines like IL-12, IL-23, TGF-beta, and IL-6.
• Identification of transcription factors such as RORgammat and Foxp3.
• Characterization of human Th17 cells using cell surface markers (CCR2, CCR5).

Main Results:

• IL-23-driven Th17 cells are pivotal in the pathogenesis of experimental autoimmune encephalomyelitis (EAE).
• TGF-beta and IL-6 induce Th17 cell lineage commitment via RORgammat.
• Human Th17 cells were identified as CCR2+ CCR5- memory CD4+ T cells.
• The IL-23/Th17 axis is implicated in various human autoimmune diseases, including MS.

Conclusions:

• The IL-23/Th17 axis plays a significant role in the pathogenesis of multiple sclerosis.
• Human Th17 cells can be identified by the CCR2+ CCR5- phenotype.
• CCR2 on Th17 cells presents a potential therapeutic target for managing MS.